My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
February 2012
Top Stories
From the President:
How Is Antimicrobial Resistance Affecting Your Patients?

Recently I treated a previously healthy 24-year-old graduate student who was brought to our emergency room. She could not keep fluids down, her blood pressure was abnormally low, she was terribly weak, and she had a fever.

Several days before, she had been treated at an urgent care center for symptoms of a urinary tract infection, but the oral antibiotic she was given (ciprofloxacin) wasn’t working. We admitted the patient to the ICU, where she was intubated, and we replenished her fluids. Her chest x-ray showed severe lung disease, consistent with acute respiratory distress syndrome. Blood and urine cultures identified the culprit: A multiply resistant strain of extended-spectrum beta lactamase (ESBL)-producing E. coli.

Fortunately, we were able to save her using a few of the remaining and effective antibiotics still left in our arsenal. She improved, was able to leave the ICU after a few days, and eventually went home, where she received IV antibiotics for another seven days.

As IDSA members well know, this patient was lucky. As resistance rates continue to rise, and the antimicrobial development pipeline remains dry, even common, everyday infections are becoming harder to treat and are increasingly life threatening. 

The next several months offer a critical window of opportunity in Washington to help address the lack of new antimicrobial development. Interest on Capitol Hill is growing, hearings have been held, and an important bill, the Generating Antibiotics Incentives Now (GAIN) Act, has been introduced in the U.S. House and Senate. IDSA is doing everything it can on many fronts on this issue. But to build on this momentum and get legislation passed in 2012, we need you, our members, to be the difference makers.

How can you help? Share a brief vignette or anecdote, like mine above, showing how antimicrobial resistance is impacting your ability to care for patients. Just 200 words or so in length, and without any patient identifying information, these accounts are powerful tools that educate policymakers and drive home the need for action. Also, visit IDSA’s “Take Action” webpage to send messages to your representatives in Congress and urge your colleagues to do the same. Stay tuned for other ways to make sure the voice of ID specialists is heard on this critical issue.

The lack of antimicrobial development coupled with the rise in drug resistance is a growing crisis that threatens patients’ lives and the very foundations of modern medical care. IDSA members know this all too well. By sharing your front-line perspectives and participating in other advocacy efforts, you can make a big difference. Please start today.

For more on IDSA’s advocacy efforts in this area, see the related article in this issue.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:

Patient Care and Science
CDC Guidance for Influenza Antivirals Remains Unchanged
Medicare Website Reports Hospital CLABSI Rates
ACIP Recommends Tdap for All Adults, Including Those 65 and Older
Drug Approvals, Recalls, Adverse Events Update
Clinical Practice Management
Medicare Physician Payment Cuts Delayed for 10 Months
Global ID
Interview Series: CDC’s Role in Global HIV and TB
Experts Highlight Role of Prevention Interventions in Global AIDS Fight
PEPFAR Takes Hit in Obama’s FY2013 Budget
Policy and Advocacy
Obama’s FY2013 Budget Mixed Bag for ID, HIV/AIDS
HHS Advisory Group Recommends Voluntary Measures to Boost HCW Influenza Vaccination
Your Colleagues
Check Out “My IDSA” for Latest Member News
Education & Resources
CDC Lyme Disease Webinar: CME Credit Available
Adolescent Vaccination Education Materials Available
Top Stories
From the President:
How Is Antimicrobial Resistance Affecting Your Patients?
IDSA Urges Congress, FDA to Boost Antibiotic R&D
IDWeek 2012 Now Accepting Abstract Submissions
IDSA Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add '' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.